Project & Abagovomab: the target population & benefits expected
The MIMOSA Trial: the target population
Women with ovarian cancer in advanced stage (Figo III - IV)
After first-line treatment with
Surgery + Chemotherapy
and Complete Response (no evidence of disease)
Entering the Mimosa study
(see www.clinicaltrials.gov for further details)
The MIMOSA Trial: Potential benefits expected from Abagovomab
     
Vaccination with
Abagovomab


1





2

3
Increased disease-free time
Increased time
without
chemiotherapy
Increased life expectancy